Sunday 18 October 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
23.44
1.63
−6.50%
Follow SRZN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 | — | — | — |
P/S ratio |
48.61 | 0.00 | — | 0.00 | — | — | — |
Altman Z-Score |
(7.50) | (8.61) | — | (2.43) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(15.54) | (18.77) | — | 1.35 | — | — | — |
P/Operating CF |
(29.08) | 12.09 | — | (95.04) | — | — | — |
Beneish M-Score |
(14.31) | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | — | 0.26 | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | — | 0.26 | — | — | — |
EV/Sales |
22.94 | 0.00 | — | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | 1.03 | — | — | — |
EV/Operating CF |
(2.64) | (0.43) | — | 1.28 | — | — | — |
EV/FCF |
(2.63) | (0.43) | — | 1.26 | — | — | — |
Quick Ratio |
9.01 | 5.07 | 5.34 | 8.00 | 7.50 | 6.76 | — |
Current Ratio |
9.22 | 5.32 | 5.75 | 8.35 | 7.75 | 6.90 | — |
Net Debt/EBITDA |
2.15 | 1.43 | 0.81 | 1.79 | 1.95 | 1.59 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.05 | 0.23 | 0.00 | 0.11 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.13 | 0.28 | 0.94 | 1.23 | 0.89 | 0.89 | — |
Capex/Depreciation |
(0.24) | (0.02) | (0.34) | (0.35) | (0.58) | (0.45) | — |
| 231.45% | (767.91%) | (75.55%) | (38.78%) | (69.62%) | (32.72%) | — | |
| (328.86%) | (134.46%) | (63.52%) | (31.78%) | (54.86%) | (105.43%) | — | |
ROIC |
0.00% | 0.00% | (1,512.29%) | (17,001.15%) | (433.10%) | 0.00% | — |
Return on Tangible Assets |
(294.93%) | (197.53%) | (119.72%) | (47.88%) | (56.68%) | (67.07%) | — |
Average Days of Receivables |
21.83 | 87.05 | 0.00 | 57.76 | — | — | — |
Research and Development Expense of Revenue |
844.55% | 198.33% | 0.00% | 296.10% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
466.03% | 141.36% | 0.00% | 158.61% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
110.30% | 38.61% | 0.00% | 36.14% | 0.00% | 0.00% | — |
Graham Net Nets |
(1.15) | (0.73) | — | 3.48 | — | — | — |
Graham Number |
137.30 | 59.75 | — | 0.00 | — | — | — |
Earnings Yield |
(147.65%) | (151.71%) | — | (185.18%) | — | — | — |
Free Cash Flow Yield |
(17.97%) | (41.94%) | — | (230.31%) | — | — | — |
Revenue per Share |
0.47 | 3.63 | 0.00 | 5.40 | 0.00 | 0.00 | — |
Operating CF per Share |
(4.04) | (6.01) | (20.00) | (19.08) | (29.64) | (27.31) | — |
Capex per Share |
(0.02) | (0.01) | (0.20) | (0.31) | (0.77) | (0.82) | — |
Free Cash Flow per Share |
(4.06) | (6.02) | (20.20) | (19.39) | (30.41) | (28.13) | — |
Cash per Share |
11.93 | 11.78 | 17.86 | 32.77 | 61.85 | 46.16 | — |
Shareholders Equity per Share |
(25.11) | (7.29) | 18.80 | 32.84 | 66.61 | 44.39 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(25.11) | (7.29) | 18.80 | 32.84 | 66.61 | 44.39 | — |
Free Cash Flow |
(30.37) | (17.65) | (40.76) | (44.87) | (50.08) | (29.97) | — |
Working Capital |
81.63 | 31.62 | 33.98 | 71.57 | 91.62 | 42.95 | — |
Capital Expenditures |
(0.13) | (0.03) | (0.40) | (0.73) | (1.27) | (0.87) | — |
Net Current Asset Value |
(194.93) | (30.91) | 32.99 | 67.87 | 77.72 | 35.46 | — |
EV/EBIT |
0.00 | 0.00 | — | 1.27 | — | — | — |
Capex to Sales |
0.04 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | — | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
1.24 | 2.57 | 0.60 | 0.57 | 0.45 | 0.33 | — |
Cash ROIC |
30.83% | (133.89%) | (55.10%) | (29.55%) | (23.67%) | (31.07%) | — |
Accounts Receivable Turnover |
2.53 | 4.54 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
1.37 | 2.35 | 2.07 | — | — | — | — |
Average Payables |
0.52 | 0.42 | 0.59 | 1.69 | 2.25 | 2.25 | — |
Average Assets |
73.60 | 47.27 | 67.76 | 113.30 | 99.62 | 31.03 | — |
Average Common Equity |
(104.57) | 8.28 | 56.97 | 92.85 | 78.50 | 99.98 | — |
Columns are period end dates